Akebia Therapeutics (AKBA) Reports Publication of Strong Vadadustat Phase 2 Data in CKD-Related Anemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2023
- S&P 500, Nasdaq rebound as Treasury yields retreat; Ford rises
- S&P 500 could end the year over 10% higher from here - Piper Sandler
- Citi says Meta shares to rally in near term on share gains, upcoming AI event
- Ads are coming to Amazon Prime Video next year; Stock pops
- 'Sell the last rate hike' strategy is in action, stocks could fall further - BofA's Hartnett
- Cisco Systems (CSCO) to acquire Splunk (SPLK) for $28 billion; Shares fall
- Cisco Systems (CSCO) to Acquire Splunk (SPLK) for $157 Per Share, $28 Billion
- Nikola (NKLA) Announces $40M Notes Offering
- Bed Bath & Beyond (BBBY) Reports Bankruptcy Court Confirmed Second Amended Joint Chapter 11 Plan of Bed Bath & Beyond and Its Debtor Affiliates
- SEC Charges Citadel Securities for Violating Order Marking Requirements of Short Sale Regulations
- Activision Blizzard, Roku, Wayfair and Citi rise premarket; Ford falls
- After-hours movers: U.S. Steel gains on new bidder, Scholastic falls following results
- FedEx, Splunk and Marvell rise premarket; Cisco, Broadcom fall
- Coty and General Mills rise premarket; Instacart, Chewy and Dollar General fall
- After-hours movers: Nano Dimension gains on buyback resumption, Steelcase up on EPS
Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
September 19, 2016 8:30 AM EDT-- Data Showed That Vadadustat Controlled Hemoglobin Levels While Improving Iron Metabolism --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the publication of positive results from a Phase 2b study of... More
